VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
|Podcasts|June 27, 2022
Pharmacy Focus: Student Edition - The Importance of Fellowship Opportunities and the Community Pharmacy Fellowship from NCPA, CPESN
We spoke with Carlie Traylor, PharmD, of the National Community Pharmacy Association to learn about a fellowship program offered by NCPA and CPESN
Advertisement
This month, we spoke with Carlie Traylor, PharmD, of the National Community Pharmacy Association (NCPA) to learn about a fellowship program offered by NCPA and CPESN that encourages innovation in the community pharmacy space.
Advertisement
Related to this article
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]-lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
AI tools in pharmacy education risk eroding critical thinking, lab competency, and patient safety if used as substitutes for foundational learning.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
What Cemdisiran Could Mean for Myasthenia Gravis Treatment and Patient Safety
3
Celebrate the Path to MTM During American Pharmacists Month
4
Navigating the Shift From Cockcroft-Gault to eGFR for Drug Dosing
5